Strophantine-G (Strophanthin-G)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceWabainWabain
Similar drugsTo uncover
  • Strophantine-G
    solution in / in 
    EXPERIMENTAL FACTORY ГНЦЛС, ООО     Ukraine
    • Dosage form: & nbspSolution for intravenous administration.
    Composition:1 ml of solution contains active substance uabain 0.25 mg;
    Excipients: acid citric monohydrate, sodium hydroxide, water for injection.
    Description:Colorless transparent liquid.
    Pharmacotherapeutic group:Cardiotonic is a cardiac glycoside.
    ATX: & nbsp

    C.01.A.C.01   Strophantine

    Pharmacodynamics:Cardiotonic, antiarrhythmic, blocks Na + / K + -ATPase of the cell membrane of cardiomyocytes. Increases the strength and heart rate (positive inotropic effect), reduces atrioventricular (AV) conductivity (negative dromotropic effect), stimulates (at sub-toxic and toxic doses) the formation of heterotopic impulses due to lowering the threshold of excitability and reduces the heart rate (HR) - negative chronotropic Effect. With heart failure increases the shock and minute volume of blood, reduces the end-diastolic volume of the ventricles, reduces the size of the heart and reduces the need for myocardium in oxygen.
    The effect manifests itself 2-10 minutes after IV injection, reaches a maximum after 30-120 minutes and lasts 1-3 days.
    Pharmacokinetics:The connection with plasma proteins - 40%, is not subject to metabolism, is excreted by the kidneys in unchanged form.
    Indications:Acute heart failure or decompensated chronic heart failure, supraventricular tachycardia, flutter and atrial fibrillation.
    Contraindications:Hypersensitivity to the drug, glycoside intoxication, Wolff-Parkinson-White syndrome, atrioventricular blockade of the II degree, intermittent complete blockade.
    Carefully:Atrioventricular blockade of the 1st degree, syndrome of sinus node weakness without an artificial pacemaker, the probability of unstable conduction at the atrioventricular node, history of Morgagni-Adams-Stokes attacks, hypertrophic subaortic stenosis, isolated mitral stenosis with a rare heart rate, cardiac asthma in patients with mitral stenosis (in the absence of tachysystolic form of atrial fibrillation), acute myocardial infarction, unstable angina, myocarditis, arteriovenous shunt, g myxia, heart failure with diastolic dysfunction (restrictive cardiomyopathy, amyloidosis of the heart,constrictive pericarditis, cardiac tamponade), extrasystole, marked dilatation of the heart cavities, "pulmonary" heart.
    Electrolyte disorders: hypokalemia, hypomagnesemia, hypercalcemia, hypernatremia.
    Hypothyroidism, alkalosis, elderly age, renal and / or hepatic insufficiency, obesity.
    Pregnancy and lactation:The safety of the use of ouabain during pregnancy and during breastfeeding has not been established, and therefore the drug should be used with caution during this period, under the strict supervision of the physician and taking into account the "benefit / risk" ratio.
    Dosing and Administration:In / in, slowly. The dose is selected individually depending on the nosology and the patient's response to therapy. At the average rate of digitalization, 1 ml (0.25 mg) 2 times a day (at an interval of 12 h) is administered during the saturation period. The duration of the saturation period averages 2 days. If necessary, you can enter an additional dose of -0.1-0.15 mg with an interval of 0.5 to 2 hours. The daily dose should not exceed 1 mg, which corresponds to 4 ml of solution for injection. The maintenance dose, as a rule, does not exceed 0.25 mg / day.
    Side effects:Most side effects are caused by a sharp drop in blood pressure.
    Frequency: very often - more than 1/10; often more than 1/100 and less than 1/10; infrequently - more than 1/1000 and less than 1/100; rarely - more than 1/10000 and less than 1/1000; very rarely - less than 1/10000, incl. individual messages.
    From the cardiovascular system: infrequent - a feeling of palpitations, tachycardia, aetiology, a feeling of compression behind the sternum, shortness of breath, arrhythmias.
    From the digestive system: often - nausea, infrequently - vomiting.
    From the central nervous system: often - dizziness, headache, fatigue; very rarely - anxiety.
    From the skin: infrequently - increased sweating.
    Allergic reactions: rarely - skin itching, redness of the skin, exanthema.
    From the urinary system: often - proteinuria; rarely - nephropathy, nephrotic syndrome.
    On the part of the reproductive system: rarely - priapism.
    Laboratory indicators: very rarely - thrombocytopenia.
    Overdose:Symptoms: the earliest signs of glycosidic intoxication - decreased appetite, vomiting, disturbances of the heart rhythm (ventricular paroxysmal tachycardia, ventricular extrasystole, incl.bigemia, polytopic ventricular extrasystole, nodular tachycardia, sinoatrial block, atrial flutter and fibrillation, atrioventricular blockade); diarrhea, abdominal pain, intestinal necrosis; coloring of visible objects in yellow-green color, flashing of flies before the eyes, reduction of visual acuity, perception of objects in a reduced or enlarged form; neuritis, radiculitis, manic-depressive syndrome, paresthesia.
    Treatment: cancellation of cardiac glycosides or a decrease in regular doses and an increase in the time intervals between administration, administration of antidotes (sodium dimercaptopropanesulfonate, sodium calcium edetate), symptomatic therapy. As antiarrhythmic drugs - preparations of I class (lidocaine, phenytoin). With hypokalemia - iv administration of KSI (6-8 g / day at a rate of 1-1-5 g for 0-5 l of 5% dextrose and 6-8 units of short-acting insulin, injected drip, for 3 hours). With severe bradycardia, atrioventricular blockade - m-holinoblokatory. Beta-adrenomimetics is dangerous because of the possible increase in the pro-arrhythmogenic effect of cardiac glycosides. With a full transverse blockade with attacks of Morgagni-Adams-Stokes - a temporary pacing.
    Interaction:Adrenomimetics, methylxanthines, reserpine, tricyclic antidepressants increase the likelihood of heart rhythm disturbances.
    Beta-blockers and antiarrhythmic drugs of the IA class, verapamil and magnesium sulfate increase the severity of AV conduction decrease.
    Quinidine, methyldopa, clonidine, spironolactone, amiodarone, verapamil, captopril, erythromycin and tetracycline increase the concentration of uabain in the blood (a competitive decrease in secretion of the proximal tubules of the kidneys).
    Glucocorticosteroids and diuretics increase the risk of hypokalemia and hypomagnesemia, angiotensin converting enzyme (ACE) blockers and angiotensin II receptor antagonists - reduce.
    Salts of calcium, catecholamines, diuretics (mostly thiazide and inhibitors of cartoanhydrase), glucocorticosteroids, insulin increase the risk of developing glycosidic intoxication.
    Special instructions:With special care apply in patients with thyrotoxicosis and atrial extrasystole.
    Given the small therapeutic latitude during treatment, careful medical supervision and individual dose selection are necessary.
    If the impaired excretory function of the kidneys should reduce the dose (prevention of glycosidic intoxication).
    The likelihood of an overdose increases with hypokalemia, hypomagnesemia, hypercalcemia, hypernatremia, marked dilatation of the heart cavities, "pulmonary" heart, alkalosis, in elderly patients.
    Special caution and ECG monitoring are required when AV conduction is disturbed.
    Effect on the ability to drive transp. cf. and fur:During the period of treatment, it is not recommended to drive vehicles and engage in other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.
    Form release / dosage:Solution for intravenous administration 0.25 mg / ml.
    Packaging:When produced at OOO "Experimental Plant" GNTSLS ", Ukraine.
    1 ml in ampoules.
    For 10 ampoules together with the instruction for use and scarifier ampoule or disk cutting ceramic in a pack of cardboard.
    If there are fracture rings or break points on the ampoule, the ampoule scarifier or ceramic cutting disc is not put into the pack.
    When manufactured at OOO "Pharmaceutical Company" Health ", Ukraine.
    1 ml in ampoules.
    For 10 ampoules together with the instruction for use and scarifier ampoule or disk cutting ceramic in a pack of cardboard.
    For 5 ampoules in a contoured cell pack of a polyvinylchloride film or a polyvinylchloride film and aluminum foil, 1 or 2 contour squares, together with an instruction for use and a scarifier or ampoule disk or a cutting ceramic disc in a pack of cardboard.
    For 10 ampoules in a contoured cell pack of a polyvinylchloride film or a polyvinylchloride film and aluminum foil, 1 contour pack together with an instruction for use and a scarifier or ampoule cutter disk in a pack of cardboard.
    If there are fracture rings or points and incisions on the ampoule, the ampoule scarifier or ceramic cutting disc is not inserted into the pack.
    Storage conditions:Store in a dark place at a temperature of 15 ° C to 25 ° C. Keep out of the reach of children.
    Shelf life:3 years.
    Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:П N016231 / 01
    Date of registration:04.02.2010 / 16.04.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:EXPERIMENTAL FACTORY ГНЦЛС, ООО EXPERIMENTAL FACTORY ГНЦЛС, ООО Ukraine
    Manufacturer: & nbsp
    Information update date: & nbsp2016-12-19
    Illustrated instructions
      Instructions
      Up